A
Spyre Therapeutics, Inc. — Earnings Quality Grade A
SYRE · Healthcare
Strong financial health
Revenue
$0M
2025
Net Income
-$155M
2025
Gross Margin
—
Free Cash Flow
-$169M
01
Screening Summary
6
Passed
1
Watch
0
Failed
—
M-Score
Management Signals
No recent CEO, CFO, board, or accounting leadership signals found in SEC 8-K filings.
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
—
A3Revenue vs CFFO
Insufficient data
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
—
B2CapEx vs Revenue
Insufficient data
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✓
C1CFFO vs Net Income
CFFO/NI = 1.09. Profits backed by cash
!
C2Free Cash Flow
FCF is negative ($-0.2B)
✓
C3Accruals Ratio
Accruals ratio = 1.8%. Low accruals
—
C4Cash vs Debt
Insufficient data
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
—
D2Leverage
Insufficient data
—
D3Soft Asset Growth
Insufficient data
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
✓
E1Serial Acquirer FCF
FCF after acquisitions positive
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
11.45
Safe Zone0 Distress1.102.605.0+ Safe
0.9245
Liquidity
-1.4498
Cumulative profit
-0.2823
Operating efficiency
11.4355
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25